Hospital
Chatham Hospital INC
Chatham Hospital INC was paid $4.69M by Medicaid between Jan 2018 and Dec 2024, across 63 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoCHATHAM HOSPITAL INC
SILER CITY, NC 27344
SILER CITY, NC 27344
33aNPI1093712655assigned 06/28/2005
33bProvider typeCritical Access Hospital
28Total paid$4.69M
24GClaims100,144
24DCodes billed63
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in North Carolina
Rank by total paid#6 of 25
Median peer was paid$1.32M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,215 | $723K | |
| 2019 | 14,498 | $703K | |
| 2020 | 10,307 | $401K | |
| 2021 | 13,690 | $675K | |
| 2022 | 14,626 | $763K | |
| 2023 | 14,333 | $646K | |
| 2024incomplete | 17,475 | $783K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 16,341 | 15,032 | $1.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 7,501 | 6,625 | $1.21M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.3% | 2,781 | 2,470 | $250K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 3,589 | 3,388 | $212K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 1,025 | 864 | $166K |
| J3490 | Unclassified drugs | 3.0% | 19,042 | 11,129 | $140K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.5% | 805 | 760 | $119K |
| 71046 | Radiologic examination, chest; 2 views | 2.1% | 1,427 | 1,346 | $100K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.1% | 1,261 | 971 | $97K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 2,042 | 1,895 | $90K |
| 80053 | Comprehensive metabolic panel | 1.9% | 9,230 | 8,357 | $88K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 9,430 | 8,544 | $75K |
51 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 849 | $62K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 44 | $58K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 1,136 | $57K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,125 | $26K |
| 81001 | <1% | 5,623 | $20K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 310 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 472 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 712 | $11K |
| 81025 | <1% | 1,257 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 420 | $10K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,447 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,015 | $9K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,339 | $9K |
| 84484 | <1% | 1,078 | $9K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 18 | $8K |
| 83690 | <1% | 1,026 | $8K | |
| 87631 | <1% | 79 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 118 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 120 | $6K |
| 87081 | <1% | 764 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 131 | $6K |
| 36592 | <1% | 399 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 59 | $5K |
| 85027 | <1% | 511 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 55 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 87 | $4K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 20 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 155 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 35 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 97 | $2K |
| 80061 | Lipid panel | <1% | 122 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 90 | $2K |
| A9270 | Non-covered item or service | <1% | 1,784 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 255 | $1K |
| 84439 | <1% | 88 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 89 | $1K |
| 87186 | <1% | 77 | $902.08 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 72 | $777.94 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 126 | $718.04 |
| 85379 | <1% | 58 | $692.85 | |
| 85610 | <1% | 187 | $646.11 | |
| 87077 | <1% | 61 | $627.97 | |
| 80076 | <1% | 41 | $414.63 | |
| 83525 | <1% | 24 | $359.04 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18 | $325.00 |
| 83605 | <1% | 14 | $171.86 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $158.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $65.79 |
| 85730 | <1% | 12 | $59.84 | |
| 82962 | <1% | 14 | $43.89 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUNCH, MICHAEL (CFO)
Parent organizationCHATHAM HOSPITAL INC.
| Provider | Location | Paid |
|---|---|---|
| Chatham Imaging Services of Pittsboro, LLC | Pittsboro, NC | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.